TY - JOUR T1 - Tofacitinib for polyarteritis nodosa: a tailored therapy JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - 2214 LP - 2216 DO - 10.1136/annrheumdis-2016-209330 VL - 75 IS - 12 AU - Doron Rimar AU - Ayelet Alpert AU - Elina Starosvetsky AU - Itzhak Rosner AU - Gleb Slobodin AU - Michael Rozenbaum AU - Lisa Kaly AU - Nina Boulman AU - Abid Awisat AU - Shira Ginsberg AU - Karina Zilber AU - Shai S Shen-Orr Y1 - 2016/12/01 UR - http://ard.bmj.com/content/75/12/2214.abstract N2 - Tofacitinib is a novel inhibitor of Janus kinase (JAK) 3 and JAK1 is recently introduced as treatment for rheumatoid arthritis.1 The JAK inhibitors are at the focus of research in a myriad of other inflammatory diseases2 ,3 as the JAK-(signal transducer and activator of transcription) STAT pathway has a central role in cytokine signal transduction. We herein describe a case of refractory polyarteritis nodosa (PAN) successfully treated with tofacitinib.A 28-year-old man had been diagnosed with PAN at age 14. He presented with livedo reticularis, arthritis and skin nodules with arteritis/fibrinoid necrosis confirmed on biopsy. Immunological panel at the time of diagnosis was negative for antineutrophil cytoplasmic antibodies, anti-nuclear antibodies, anti-Ro/SS-A antibodies, anti-La/SS-B antibodies, rheumatoid factor, with normal complement levels. He was treated with azathioprine and methotrexate for several years with drug-controlled complete remission. At age 24, his disease flared and he began to suffer from necrotic lesions of the scrotum and calves, excruciating abdominal pain and polyarthritis, with high C-reactive protein (CRP) levels (160–300 mg/L) for which he received recurrent intravenous methylprednisolone pulses and oral … ER -